Drugs Made In America Acquisition Corp.
DMAANasdaqFinancials · Blank Checks · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | |
|---|---|---|
| Revenue | — | — |
| Operating income | −$2.8M | −$279,845 |
| Net income | $5.9M | −$279,845 |
| Total assets | $239.9M | $550,824 |
| Total liabilities | $7.3M | $795,669 |
| Equity | −$7.3M | −$244,845 |
| EPS (diluted) | — | $-0.03 |
| Shares out. | 33.5M | 9.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −81.8%
- Return on assets
- 2.5%
- Return on capital (ROCE)
- −1.2%
- Liabilities / assets
- 3.0%
- Debt / equity
- —
- Book value / share
- $-0.22
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -1.24distress
- Accruals / assets
- 2.7%clean
- Piotroski F-Score
- 4/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 severe● 1 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2026
- NT 10-Qmissed a reporting deadline ↗Nov 17, 2025
- NT 10-Qmissed a reporting deadline ↗May 15, 2025
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Mizuho Financial Group IncPassive (13G)May 14, 2026
- Hudson Bay Capital Management LpPassive (13G)Nov 12, 2025
- Karpus Management, Inc.Passive (13G)Aug 14, 2025
- First Trust Capital Management L.P.Passive (13G)May 15, 2025
- Polar Asset Management Partners Inc.Passive (13G)May 15, 2025
- Glazer Capital, LlcPassive (13G)May 15, 2025
- Drugs Made In America Acquisition LlcActivist (13D)Mar 3, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Drugs Made In America Acquisition Llc10% owner | Feb 18, 2025 | Buy | 30,000 | — |
| Stockwell LynnOfficer — CEO and Exe. Chair of Board | Feb 18, 2025 | Buy | 30,000 | — |
| Drugs Made In America Acquisition Llc10% owner | Jan 29, 2025 | Buy | 400,000 | — |
| Stockwell LynnOfficer — CEO and Executive COB | Jan 29, 2025 | Buy | 400,000 | — |
| Shulgan Myron W.Director | Jan 29, 2025 | J | 100,000 | — |
| Prasad Sridhar G.Director | Jan 29, 2025 | J | 100,000 | — |
| Do CatherineDirector | Jan 29, 2025 | J | 100,000 | — |
| Worman Glenn C.Officer — CFO | Jan 29, 2025 | J | 100,000 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 96,507 | 13.1 | -7.0% |
| Apr 30, 2026 | 103,808 | 1.0 | -92.9% |
| Apr 15, 2026 | 1.5M | 4.0 | +8397.5% |
| Mar 31, 2026 | 17,252 | 1.0 | -30.6% |
| Mar 13, 2026 | 24,866 | 1.0 | -11.9% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreementMay 5, 2026
- Amended charter or bylaws · Shareholder vote · Other material eventMay 1, 2026
- Entered a material agreementApr 28, 2026
- Other material eventApr 8, 2026
- Entered a material agreement · New financial obligation · Other material eventMar 27, 2026
- Other material eventMar 6, 2026
- Director / officer changeMar 6, 2026
- Director / officer changeNov 18, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QQUARTERLY REPORTMay 14, 2026
- SCHEDULE 13GMay 14, 2026
- 425CURRENT REPORTMay 5, 2026
- 8-KCURRENT REPORTMay 5, 2026
- 8-KCURRENT REPORTMay 1, 2026
- 8-KCURRENT REPORTApr 28, 2026
- DEFR14AREVISED DEFINITIVE PROXY STATEMENTApr 16, 2026
- 10-KANNUAL REPORTApr 15, 2026
- DEF 14APROXY STATEMENTApr 14, 2026
- 8-KCURRENT REPORTApr 8, 2026
- NT 10-KNOTIFICATION OF LATE FILINGApr 1, 2026
- PRE 14APROXY STATEMENTMar 27, 2026
- 8-KCURRENT REPORTMar 27, 2026
- 8-KCURRENT REPORTMar 6, 2026
- 8-KCURRENT REPORTMar 6, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.